Genetic
CAR-BCMA T cells
CAR-BCMA T cells is a genetic therapy with 3 clinical trials. Currently 1 active trials ongoing.
Total Trials
3
Max Phase
—
Type
GENETIC
Molecule
—
Success Metrics
Active Trials
1(33%)
Phase Distribution
Ph phase_1
2
67%
Ph not_applicable
1
33%
Phase Distribution
2
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
N/ANon-phased studies
1(33.3%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Other(2)
Detailed Status
unknown2
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 1
Trials by Phase
Phase 12 (66.7%)
N/A1 (33.3%)
Trials by Status
unknown267%
active_not_recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
active_not_recruitingphase_1
Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)
NCT03975907
unknownnot_applicable
Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma
NCT03380039
unknownphase_1
Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma
NCT03716856
Clinical Trials (3)
Showing 3 of 3 trials
NCT03975907Phase 1
Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)
NCT03380039Not Applicable
Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma
NCT03716856Phase 1
Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma
All 3 trials loaded
Drug Details
- Intervention Type
- GENETIC
- Total Trials
- 3